Amtoft H W, Sørensen A B, Bareil C, Schmidt J, Luz A, Pedersen F S
Department of Molecular and Structural Biology, University of Aarhus, Aarhus C, Denmark.
J Virol. 1997 Jul;71(7):5080-7. doi: 10.1128/JVI.71.7.5080-5087.1997.
Murine retrovirus SL3-3 is highly T lymphomagenic. Its pathogenic properties are determined by the transcriptional enhancer of the U3 repeat region which shows preferential activity in T cells. Within the U3 repeats, the major determinant of T-cell specificity has been mapped to binding sites for the AML1 transcription factor family (also known as the core binding factor [CBF], polyomavirus enhancer binding protein 2 [PEBP2], and SL3-3 enhancer factor 1 [SEF-1]). SL3-3 viruses with AML1 site mutations have lost a major determinant of T-cell-specific enhancer function but have been found to retain a lymphomagenic potential, although disease induction is slower than for the SL3-3 wild type. To compare the specificities and mechanisms of disease induction of wild-type and mutant viruses, we have examined lymphomas induced by mutant viruses harboring transversions of three consecutive base pairs critical to AML1 site function (B. Hallberg, J. Schmidt, A. Luz, F. S. Pedersen, and T. Grundström. J. Virol. 65:4177-4181, 1991). Our results show that the mutated AML1 sites are genetically stable during lymphomagenesis and that ecotropic provirus numbers in DNA of tumors induced by wild-type and mutant viruses fall within the same range. Moreover, proviruses were found to be integrated at the c-myc locus in similar proportions of wild-type and mutant SL3-3-induced tumors, and the mutated AML1 sites of proviruses at c-myc are unaltered. In some cases, however, including one c-myc-integrated provirus, a single-base pair change was detected in a second, weaker AML1 binding site. By DNA rearrangement analysis of the T-cell receptor beta-locus, tumors induced by the AML1 site mutants are found to be of the T-cell type. Thus, although the AML1 site mutants have weakened T-cell-specific enhancers they are T-lymphomagenic, and wild-type- and mutant-virus-induced tumor DNAs are similar with respect to the number of overall ecotropic and c-myc-integrated clonal proviruses. The SL3-3 wild-type and AML1 site mutant viruses may therefore induce disease by similar mechanisms.
小鼠逆转录病毒SL3-3具有高度的T淋巴瘤致瘤性。其致病特性由U3重复区域的转录增强子决定,该增强子在T细胞中表现出优先活性。在U3重复序列中,T细胞特异性的主要决定因素已定位到AML1转录因子家族(也称为核心结合因子[CBF]、多瘤病毒增强子结合蛋白2[PEBP2]和SL3-3增强子因子1[SEF-1])的结合位点。具有AML1位点突变的SL3-3病毒失去了T细胞特异性增强子功能的主要决定因素,但已发现其仍保留淋巴瘤致瘤潜力,尽管疾病诱导比SL3-3野生型慢。为了比较野生型和突变型病毒诱导疾病的特异性和机制,我们检测了携带对AML1位点功能至关重要的三个连续碱基对颠换的突变病毒诱导的淋巴瘤(B. Hallberg、J. Schmidt、A. Luz、F. S. Pedersen和T. Grundström。《病毒学杂志》65:4177-4181,1991)。我们的结果表明,在淋巴瘤发生过程中,突变的AML1位点在遗传上是稳定的,并且野生型和突变型病毒诱导的肿瘤DNA中亲嗜性前病毒数量在同一范围内。此外,发现前病毒以相似比例整合到野生型和突变型SL3-3诱导肿瘤的c-myc基因座,并且c-myc处前病毒的突变AML1位点未改变。然而,在某些情况下,包括一个整合到c-myc的前病毒,在第二个较弱的AML1结合位点检测到一个单碱基对变化。通过对T细胞受体β基因座的DNA重排分析,发现AML1位点突变体诱导的肿瘤是T细胞类型。因此,尽管AML1位点突变体的T细胞特异性增强子减弱,但它们仍具有T淋巴瘤致瘤性,并且野生型和突变型病毒诱导的肿瘤DNA在总体亲嗜性和c-myc整合的克隆前病毒数量方面相似。因此,SL3-3野生型和AML1位点突变型病毒可能通过相似机制诱导疾病。